EZH2/miR-138轴失调通过下调RBPMS导致多发性骨髓瘤耐药
本研究探讨EZH2在多发性骨髓瘤耐药中的分子机制。EZH2在耐药细胞中上调且与不良预后相关,其过表达使亲本细胞耐药,抑制EZH2则相反。miR-138为EZH2调节因子并被EZH2诱导的H3K27三甲基化抑制。RBPMS为EZH2直接靶点,其沉默导致耐药,miR-138过表达恢复RBPMS可使耐药细胞重新敏感。体内递送miR-138模拟物或EZH2药理抑制剂联合硼替佐米可使异种移植瘤显著消退。
要点
- EZH2在耐药多发性骨髓瘤细胞中上调,其过表达与不良预后相关。
- miR-138被EZH2诱导的H3K27三甲基化抑制,RBPMS是EZH2直接靶点,其沉默导致耐药。
- miR-138过表达恢复RBPMS可使耐药细胞重新敏感,体内联合硼替佐米可显著消退肿瘤。
核心结论
- EZH2/miR-138轴是潜在的多发性骨髓瘤治疗靶点。
研究设计与样本
- 研究使用多发性骨髓瘤细胞系、原代肿瘤细胞和异种移植模型,未明确样本量。
主要发现
- EZH2在耐药多发性骨髓瘤细胞中上调,其异常过表达与患者不良预后相关。
- 亲本多发性骨髓瘤细胞中过表达EZH2使其对抗骨髓瘤药物耐药,抑制EZH2则显示相反效果。
- miR-138被鉴定为EZH2的调节因子,在耐药细胞系和原代肿瘤细胞中被EZH2诱导的H3K27三甲基化抑制。
- RBPMS是EZH2的直接功能相关靶点,RBPMS沉默使多发性骨髓瘤细胞耐药,miR-138过表达恢复RBPMS可使耐药细胞重新敏感。
- 体内递送miR-138模拟物或EZH2药理抑制剂联合硼替佐米可使异种移植模型肿瘤显著消退。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
EZH2 is highly expressed in multiple myeloma (MM). However, the molecular mechanisms underlying EZH2 overexpression and its role in drug resistance of MM remain undefined. Here we show that EZH2 is upregulated in drug-resistant MM cells and its aberrant overexpression is associated with poor prognosis of MM patients. Overexpression of EZH2 in parental MM cells renders them resistant to anti-myeloma drugs and suppression of EZH2 displays the opposite effects. Using miRNA target scan algorithms, we identify miR-138 as a regulator of EZH2, which is conversely repressed by EZH2-induced H3K27 trimethylation in MM-resistant cell lines and primary tumor cells. Analysis of ChIP-seq dataset and H3K27me3 ChIP reveals that RBPMS is a direct and functionally relevant target of EZH2. RBPMS silencing confers resistance to MM cells and restoration of RBPMS by miR-138 overexpression re-sensitizes the resistant cells to drug. Importantly, in vivo delivery of miR-138 mimics or pharmacological inhibitor of EZH2 in combination with a proteasome inhibitor, bortezomib, induces significant regression of tumors in xenograft model. This study establishes EZH2/miR-138 axis as a potential therapeutic target for MM.
引用
- Rastgoo N, Pourabdollah M, Abdi J, et al. Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS. Leukemia. 2018. PMID: 29743723. doi:10.1038/s41375-018-0140-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。